解放军医学院学报
解放軍醫學院學報
해방군의학원학보
Academic Journal of Chinese Pla Medical School
2015年
10期
991-995,999
,共6页
益生菌%肝硬化%自发性腹膜炎%Meta 分析
益生菌%肝硬化%自髮性腹膜炎%Meta 分析
익생균%간경화%자발성복막염%Meta 분석
probiotics%liver cirrhosis%spontaneous bacterial peritonitis%meta-analysis
目的：系统评价益生菌预防肝硬化自发性腹膜炎(spontaneous bacterial peritonitis，SBP)的有效性。方法计算机检索2000年1月-2015年3月 Pubmed、Cochrane 图书馆、中国知网全文期刊数据库(China National Knowledge Internet， CNKI)、万方数据库、中国期刊全文数据库(Chinese Journal Full-Text Database，CJFD)、中国生物医学文献数据库(Chinese BioMedical Literature Database，CBM)、维普数据库发表的益生菌预防肝硬化发生 SBP 相关的随机对照试验，2名评价员独立负责对纳入文章质量的评价和数据的提取，用 RevMan5.2软件统计分析。结果10个随机对照试验共789例患者纳入研究，其中观察组(益生菌+护肝药物治疗)371例，对照组(护肝药物治疗)418例。Meta 分析结果显示，预防 SBP 发生的有效性益生菌制剂优于安慰剂(OR=0.34，95% CI ：0.22-0.53，P ＜0.0001)，且与抗生素无统计学差异(OR=0.78，95% CI ：0.43-1.44，P ＞0.05)。结论益生菌能够预防肝硬化患者 SBP 的发生，其有效性与抗生素相当。
目的：繫統評價益生菌預防肝硬化自髮性腹膜炎(spontaneous bacterial peritonitis，SBP)的有效性。方法計算機檢索2000年1月-2015年3月 Pubmed、Cochrane 圖書館、中國知網全文期刊數據庫(China National Knowledge Internet， CNKI)、萬方數據庫、中國期刊全文數據庫(Chinese Journal Full-Text Database，CJFD)、中國生物醫學文獻數據庫(Chinese BioMedical Literature Database，CBM)、維普數據庫髮錶的益生菌預防肝硬化髮生 SBP 相關的隨機對照試驗，2名評價員獨立負責對納入文章質量的評價和數據的提取，用 RevMan5.2軟件統計分析。結果10箇隨機對照試驗共789例患者納入研究，其中觀察組(益生菌+護肝藥物治療)371例，對照組(護肝藥物治療)418例。Meta 分析結果顯示，預防 SBP 髮生的有效性益生菌製劑優于安慰劑(OR=0.34，95% CI ：0.22-0.53，P ＜0.0001)，且與抗生素無統計學差異(OR=0.78，95% CI ：0.43-1.44，P ＞0.05)。結論益生菌能夠預防肝硬化患者 SBP 的髮生，其有效性與抗生素相噹。
목적：계통평개익생균예방간경화자발성복막염(spontaneous bacterial peritonitis，SBP)적유효성。방법계산궤검색2000년1월-2015년3월 Pubmed、Cochrane 도서관、중국지망전문기간수거고(China National Knowledge Internet， CNKI)、만방수거고、중국기간전문수거고(Chinese Journal Full-Text Database，CJFD)、중국생물의학문헌수거고(Chinese BioMedical Literature Database，CBM)、유보수거고발표적익생균예방간경화발생 SBP 상관적수궤대조시험，2명평개원독립부책대납입문장질량적평개화수거적제취，용 RevMan5.2연건통계분석。결과10개수궤대조시험공789례환자납입연구，기중관찰조(익생균+호간약물치료)371례，대조조(호간약물치료)418례。Meta 분석결과현시，예방 SBP 발생적유효성익생균제제우우안위제(OR=0.34，95% CI ：0.22-0.53，P ＜0.0001)，차여항생소무통계학차이(OR=0.78，95% CI ：0.43-1.44，P ＞0.05)。결론익생균능구예방간경화환자 SBP 적발생，기유효성여항생소상당。
Objective To systematically review the efficacy of probiotics in prevention of spontaneous bacterial peritonitis in patients with cirrhosis. Methods Pubmed, Cochrane Library, China National Knowledge Internet (CNKI), Chinese Biomedical Literature Database (CBM), Chinese Journal Full-Text Database (CJFD), Wanfang database, and CQVIP database (from January 2000 to March 2015) were searched to collect randomized controlled trials (RCTs) which comparing the efficacy of probiotics combined with or without other treatments to placebo in the prevention of spontaneous bacterial peritonitis in patients with cirrhosis. Two reviewers independently evaluated the quality of included articles and extracted the data. Statistical analysis was performed using Review Manager 5.2. Results Ten essays were enrolled in this research which included totally 789 cases. Of the 789 cases, 371 cases were in observation group (treated by probiotics and liver protection drugs) and 418 cases were in control group (treated by liver protection drugs). Meta analysis showed that in the prevention of spontaneous bacterial peritonitis, probiotics were superior to placebo (OR =0.34, 95% CI: 0.22-0.53, P < 0.000 1) and no significant differences were observed between probiotics and antibiotics (OR=0.78, 95% CI: 0.43-1.44, P > 0.05). Conclusion Probiotics and antibiotic are effective in preventing spontaneous peritonitis in patients with hepatic cirrhosis.
